We Should Desist Using RECIST, at Least in GIST

Benjamin, Robert S.; Choi, Haesun; Macapinlac, Homer A.; Burgess, M. A.; Patel, Shreyaskumar; Chen, Lei L.; Podoloff, Donald A.; Charnsangavej, C.

doi:10.1200/jco.2006.07.3411

Cited by 519 publications

(335 citation statements)

References 12 publications

Supporting

Mentioning

324

Contrasting

Unclassified

Order By: Relevance

“…In fact, targeted therapies, which act by inactivating cell signaling rather than inducing DNA damages, tend to give an acute response that hardly produces significant tumor regression, and in some instances, a senescence response has actually been reported (41). In these cases, diagnostic imaging modalities that evaluate the metabolic activity (positron emission tomography) turn out more effective (42).…”

Section: Discussionmentioning

confidence: 99%

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers

Santarosa

Col

Tonin

et al. 2009

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

BRCA1-associated tumors are characterized by an elevated genomic instability and peculiar expression profiles. Nevertheless, tailored treatments for BRCA1 mutation carriers have only been partially investigated up to now. The implementation of therapeutic strategies specific for these patients has been in part hindered by the paucity of proper preneoplastic and neoplastic BRCA1-deficient tumor cell models. In this study, we took advantage of the RNA interference technology to generate a series of partially transformed (HBL100) and tumorigenic (MCF7 and T47D) breast cancer cell lines in which BRCA1 expression was silenced at different levels. These cell models were probed by clonogenic assay for their response to several DNA-damaging agents commonly used in cancer therapy (mitomycin C, cisplatin, doxorubicin, and etoposide). Our models confirmed the peculiar sensitivity to interstrand cross-link inducers associated with BRCA1 deficiency. Intriguingly, the increased sensitivity to these compounds displayed by BRCA1-defective cells was not correlated with the extent of apoptotic cell death but rather associated to an increased fraction of growth-arrested, enlarged, multinucleated β-galactosidase-positive senescent cells. Overall, our results support a role for BRCA1 in the regulation of interstrand cross-link-induced premature senescence and suggest a reconsideration of the therapeutic power of mitomycin/platinum-based treatments in BRCA1 carriers. Moreover, our data further prompt the setup of strategies for the imaging of the senescence response in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers

Santarosa

Col

Tonin

et al. 2009

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Recently, FDG-PET has been shown to be highly sensitive in detecting early responses in patients with GISTs; it has also been shown to be useful in the prediction of long-term responses to imatinib mesylate (1)(2)(3)(4)(5)(6)8). However, FDG-PET has been rarely used to report liver metastases in gastric adenocarcinoma.…”

Section: Hepatic Metastases Of Gastric Adenocarcinoma Showing Metabolmentioning

confidence: 99%

Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT

et al. 2009

View full text Add to dashboard Cite

“…An alternate response criteria known as the Choi Criteria have previously been proposed as a tool for evaluating response to TKI therapy in place of RECIST [12,13]. In gastrointestinal stromal tumors (GISTs), treated with the TKI imatinib, the use of Choi Criteria was found to correlate with progression-free and disease-specific survival, whereas RECIST response did not [12].…”

Section: Introductionmentioning

confidence: 99%

Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria

Swiecicki¹,

Dickerson²,

Bell³

et al. 2017

Otolaryngol

View full text Add to dashboard Cite

Objective: The purpose of this study was to explore the utility of the Choi Criteria in judging response to axitinib therapy in unresectable recurrent or distant metastatic head and neck squamous cell carcinoma.Methods: Radiologic and clinical data was evaluated in a retrospective fashion from a single-arm phase II clinical trial of axitinib for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. Twenty-nine patients had imaging to which the Choi Criteria were applied in an exploratory fashion. Responses rates by Choi Criteria were compared to those identified by RECIST v1.0 and statistical analyses were performed to evaluate significance. Association of best response to survival was also examined for each criteria (RECIST v1.0 and Choi). Results:Application of the Choi Criteria demonstrated that 65.5% of patients achieved a partial response versus 6.9% by RECIST v1.0. Disease control rate was identical by Choi Criteria and RECIST v1.0 at 72.4%. Response to therapy based on Choi Criteria correlated to significantly improved estimated overall survival at 12 months (63% vs. 20%, p=0.03), whereas response to therapy based on RECIST was not a significant predictor of survival. Conclusion:The Choi Criteria appear to better identify patients responding to therapy with the anti-angiogenic tyrosine kinase inhibitor axitinib versus RECIST v1.0 in this exploratory analysis. Use of the Choi Criteria to guide treatment decisions in further studies utilizing axitinib in this population may better identify patients benefiting from therapy.

show abstract

We Should Desist Using RECIST, at Least in GIST

Cited by 519 publications

References 12 publications

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers

Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT

Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria

Contact Info

Product

Resources

About